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Abstract 
Human immunodeficiency virus theranostics facilitates the development of long acting (LA) antiretroviral 
drugs (ARVs) by defining drug-particle cell depots. Optimal drug formulations are made possible based on 
precise particle composition, structure, shape and size. Through the creation of rod-shaped particles of 
defined sizes reflective of native LA drugs, theranostic probes can be deployed to measure particle-cell 
and tissue biodistribution, antiretroviral activities and drug retention.  
Methods: Herein, we created multimodal rilpivirine (RPV) 177lutetium labeled bismuth sulfide nanorods 
(177LuBSNRs) then evaluated their structure, morphology, configuration, chemical composition, biological 
responses and adverse reactions. Particle biodistribution was analyzed by single photon emission 
computed tomography (SPECT/CT) and laser ablation inductively coupled plasma mass spectrometry 
(LA-ICP-MS) imaging.  
Results: Nanoformulated RPV and BSNRs-RPV particles showed comparable physicochemical and cell 
biological properties. Drug-particle pharmacokinetics (PK) and biodistribution in lymphoid tissue 
macrophages proved equivalent, one with the other. Rapid particle uptake and tissue distribution were 
observed, without adverse reactions, in primary blood-derived and tissue macrophages. The latter was 
seen within the marginal zones of spleen.  
Conclusions: These data, taken together, support the use of 177LuBSNRs as theranostic probes as a 
rapid assessment tool for PK LA ARV measurements. 
Key words: Long acting antiretroviral therapy, Laser ablation inductively coupled plasma mass spectrometry, 
Single photon emission computed tomography, Drug biodistribution, Multimodal imaging 
Introduction 
Current management of human immuno-
deficiency virus type one (HIV-1) infection has 
transformed clinical outcomes from a life-threatening 
disease to a chronic manageable medical condition.[1, 
2] Nonetheless, required lifelong daily dosing of 
combination antiretroviral therapy (ART) has 
limitations for regimen adherence and in pill 
fatigue.[3, 4] Recently the prospect of broad 
dissemination of antiretroviral drugs (ARVs) to 
virus-infected and susceptible people has led to the 
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notion that improved therapeutic regimen adherence 
could eliminate the acquired immunodeficiency 
(AIDS) epidemic.[5, 6] However, complete 
elimination requires more effective clinical outcomes 
for both pre-exposure prophylaxis and treatment 
regimens.[7] Moreover, recent studies suggest that 
total HIV-1 elimination could be achieved by excision 
of integrated HIV-1 DNA or through the use of 
broadly neutralizing antibodies. However, these 
treatments are years from human use, which 
underscores the immediate need for better 
antiretroviral regimens.[8-11]  
One pathway forward to affect patient treatment 
outcomes is by long-acting (LA) ARV 
injectables.[12-15] These new deliverables hold 
considerable promise towards improving patient 
adherence and affecting reduction of viral reservoirs. 
This is made possible by changing pharmacological 
management to affect drug efficacy. Such approaches 
eliminate the requirements for lifelong daily pills. 
Nonetheless, a number of challenges exist to 
implement such regimens. These include, but are not 
limited to, required dosing volumes, frequencies of 
injection, untoward side effects, and maintenance of 
antiretroviral efficacy.[16-18] Even more importantly, 
only two LA ARVs are currently in the pipeline.[12] 
Such limitations in drug choices preclude alternative 
therapies when required by either developed 
resistance mutations or adverse events. To these ends, 
our laboratories have employed ARV chemical 
modifications to create novel LA prodrug libraries 
designed to extend drug half-life and enhance 
bioavailability.[13, 14, 19-22] Notwithstanding, these 
novel prodrugs ensure drug penetration into 
“putative” viral reservoirs and sustain maximal 
antiretroviral activities.[15, 23] We posit that develop-
ment can be accelerated by modeling drug delivery, 
pharmacokinetics (PK), and biodistribution (BD).  
HIV theranostics, if appropriately implemented, 
would accelerate the development of LA ARVs by 
predicting real-time drug biodistribution and 
potency.[24, 25] The creation of theranostic probes 
would serve to speed bench to bedside research in the 
development of the most effective LA ARV 
nanoformulations. Thus, we sought to engineer 
nanoparticles that mimicked LA ARV particles in 
shape and morphology while optimizing size and 
design. To these ends, the use of bismuth (Bi) and 
sulfur (S) proved to be a natural choice as the 
components add a heavy metal detector, proven 
bioimaging capabilities and rapid oxidative 
decompositions required for human translation.[26, 
27] Intrinsically-radiolabeled 177lutetium (177Lu) 
bismuth sulfide nanorods (177LuBSNRs) were created 
as multimodal imaging particles to serve as probes for 
drug biodistribution of LA nanoformulated rilpivirine 
(NRPV). RPV, a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), was chosen as a model for other 
LA ARVs based on its highly hydrophobic and 
protein binding properties as well as extended plasma 
half-life.[24] We used 177LuBSNRs as imaging probes 
to mirror the structure, morphology, biological 
properties and atomic configuration of the 
177LuBSNRs of LA NRPV. Biodistribution of 
177Lu/BSNRs/RPV into lymphoid tissue 
macrophages was demonstrated in Balb/c mice using 
single photon emission computed tomography 
(SPECT) and laser ablation inductively coupled 
plasma mass spectrometry (LA-ICP-MS). The 
BSNRs/RPV particles demonstrated potent 
antiretroviral activities in cell-based assays. These 
data, taken together, demonstrate that these 
multimodal particles can be effective imaging probes 
for assessing LA NRPV biodistribution. The work 
demonstrates their translational application for 
determining LA ARV PK and pharmacodynamics 
(PD). 
Results  
Creation of 177LuBSNRs particles 
Chelator-free, 177LuBSNRs nanocrystals were 
first synthesized by solvothermal precipitation of 
bismuth neodecanoate and thioacetamide in the 
presence of oleic acid, oleylamine and ethanol. The 
crystallinity, monodispersity, shape, and size of the 
particles were monitored during synthesis, and 
optimized by varying time intervals and molar ratios 
of bismuth and thiol precursors. During synthesis, 
oleyl amine served as ligand and solvent with 
bismuth.[28] The prepared 177LuBSNRs were 
dispersed in cyclohexane and converted to a freely 
dispersed hydrophilic solution in the aqueous phase. 
To ensure biocompatibility, the hydrophobic 
177LuBSNRs particles were coated with biocompatible 
lipids. Lipid coated 177LuBSNRs were synthesized by 
a simple film hydration technique to make uniform 
preparations more appropriate for biological use than 
uncoated hydrophobic particles. L-α-phosphatidyl-
choline and DSPE-PEG2000 were used to functionalize 
the particles. An experimental outline is presented in 
the schematics diagram (Supplementary Figure S1 
top panel). The plain, non-lipid coated and 
non-radiolabeled BSNRs were characterized by 
various techniques. Low power TEM revealed that the 
plain non-radiolabeled BSNRs nanocrystals had a rod 
shape, of approximately 12 nm in diameter by 70 nm 
in length (Figure 1A). High resolution (HR)-TEM 
images (Figure 1B-C) show the lattice fringes with 
spacings of 0.356 and 0.194 nm. These are in accord 
with spacing planes of [130] and [431] of the atomic 
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configuration of BSNRs. The selected area electron 
diffraction (SAED) patterns of the BSNRs are shown 
by simulation indexation (Figure 1D). The lines 
correspond to the rod’s interplanar spacing.[29] 
High-angle annular dark-field scanning TEM 
(HAADF-STEM) illustrate bismuth (Bi) (red) and 
sulfur (green) (Figure 1E). The XRD shown in Figure 
1F reveals that all peaks are indexed into an 
orthorhombic crystal (JCPDS no. 01-089-8963), 
indicating high quality of crystallization. The XRD 
patterns of the BSNRs match with reported values in 
the literature.[30-32] BSNRs present peaks that are 
assignable to the orthorhombic structure (JCPDS no. 
01-089-8963). BSNRs are elongate along the [130] 
direction, representing the crystal plane of the 
longitudinal direction (Figure 1C). The energy 
dispersive X-ray spectroscopy (EDX) analysis 
demonstrated “Bismuth” and “sulfur” signals were 
detected in the BSNRs; whereas the copper peaks 
originated from the TEM grid (Figure 1F). The percent 
metal ions distributed in single particles are 81.68 and 
18.32 weight percent of bismuth and sulfur, 
respectively, as seen in the inset of Figure 1F (Right 
top panel) and these results were similar to X-ray 
fluorescence (XRF) analysis results (Supplementary 
figure S3). The mean hydrodynamic size of BSNRs by 
laser-light scattering is illustrated in Figure 1G. The 
size is ~ 205 nm and equivalent to that of NRPV 
(Table 1) (Supplementary Figure S1).[33] Phantom 
near infrared (NIR) fluorescence images of particles 
are shown in Figure 1G. Synthesis and characteriza-
tion results indicate that 177LuBSNRs could be 
employed to design a potential multi-modal 
theranostics agent that integrates SPECT and NIR 
imaging for a real-time non-invasive visualization of 
the virus sanctuary sites, which may provide more 
complementary, effective, and accurate information 
on progress of HIV-I spread with delivery drugs at 
the sanctuary sites. Non-radioactive LuBSNRs and 
BSNRs-RPV particles synthesis and characterization 
results were similar to that of radioactive particles 
(Supplementary SR1 and figure S2, S4-5) and 
Table 1. 
Radiolabeling stability assessment 
In order to accurately localize our nanoparticles 
by SPECT imaging, we verified that the radiolabel 
remained stably associated within the nanoparticle to 
preclude false positive signals in the SPECT scans that 
would result if the radiolabel dissociates from the 
particle. We developed a process of intrinsically 
doping 177Lu atoms into the crystal lattice structure 
(formed by regular repeating units of bismuth and 
sulfur) of the BSNRs, creating a unique radiolabel 
nanoprobe for in vivo studies. The stability results are 
summarized in Table 2. 177LuBSNRs were incubated 
for 3 days at 4ºC or 37ºC in either PBS (pH 7.4) or rat 
plasma. Every 24 hours, the percent radioactivity left 
in the nanoparticles was calculated. Over the course of 
72 hours in PBS at 4ºC or 37ºC, nanoparticles lost 
approximately 30% of their radioactivity, with 72% 
and 66% remaining, respectively. In 4ºC and 37ºC 
plasma, particles lost approximately 50% 
radioactivity, with 51% and 56%, remaining, 
respectively. 177BSNRs particles lost approximately 
30% of their radioactivity when incubated in PBS for 
72 hours. This can be attributed to the fact that some 
sample is lost (about 10-15%) each time the 
nanoparticles are pipetted, as the BSNRs particles 
“stick” to the inside of the pipette tip during these 
experiments. The greater loss of radioactivity in 
plasma can be attributed to the association of BSNRs 
with lipids and lipoproteins present in the rat plasma. 
We believe this to be the most likely explanation 
because we intrinsically doped the BSNRs particles. In 
this system the 177Lu ions exist in a tight coordination 
with bismuth and sulfur atoms within the core of 
nanoparticle which is shielded by an external lipid 
layer.[33] These nanoparticles, along with other lipid 
coated nanoparticles are known to form associations 
with lipids and proteins both in vivo and when 
incubated in plasma in vitro. These lipids and 
lipoproteins do not pellet when subject to the 
centrifugation applied in this experiment and instead 
remain floating atop the supernatant. Typically, lipids 
and lipoproteins will not pellet unless subjected to 
ultracentrifugation.[34] This leads to a higher reading 
in the supernatant (due to floating, lipid bound 
BSNRs particles) and a lower reading in the pellet, 
potentially masking the true stability of the radiolabel 
to the particle. Overall, these results demonstrate that 
177Lu-labeled particles are stable, with half-lives that 
mirror the expected decay of 177Lu intrinsically doped 
within nanoparticle cores. 
Table 1. Physicochemical characteristics of NRPV and 
BSNRs-RPV particles. 
Characteristics Formulations 
NRPV BSNR-RPV 
Size, nm (DLS)  341.1 205.3  
PDI (DLS)  0.22 0.31  
Core size, nm (TEM)  ~287.14 (L) X ~158.75 (W) ~70 (L) X ~12 (W)  
Drug content (%)  ~83.0 ~ 3.50  
Table 2. Radiolabeling stability of 177LuBSNR in rat plasma and 
PBS at 4ºC and 37ºC. 
Time points 
(hours) 
177LuBSNRs labeling efficiency (%) 
4°C 37°C 
PBS Plasma PBS Plasma 
0 100 100 100 100 
24 88.8 ± 1.0 81.8 ± 1.0 86.9 ± 2.8 80.7 ± 1.3 
48 87.1 ± 4.3 60.3 ± 6.1 72.2 ± 3.2 64.7 ± 5.0 
72 72.6 ± 1.6 51.2 ± 7.8 66.3 ± 0.6 56.2 ± 0.9 
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MDM particle uptake, retention and release 
assessments 
Time-dependent uptake of the BSNRs-RPV 
particles at 12.5 and 25 µg/mL by human 
monocyte-derived macrophages (MDM) was 
observed over 8 hours (Figure 2A left panels). As 
expected, treatment with 25 μg/mL of BSNRs-RPV 
provided increased particle uptake compared to the 
12.5 μg/mL treatment. Intracellular bismuth and RPV 
levels were 11.78 μg/106 cells for bismuth and 3.51 
μg/106 cells for RPV with the lower concentration 
treatment and 19.32 μg/106 for bismuth and 8.28 
μg/106 cells for RPV with the higher concentration 
treatment at 8 hours. With particles left in the cell 
culture media, the cellular uptake reaches equilibrium 
within 8 hours. In retention studies, removal of 
particles from the media led to gradual diminution of 
intracellular particles (Figure 2A right panels). The 
amount of bismuth and RPV remaining in MDM 
treated with 25 μg/mL of particles after five days was 
51.5% and 54.5%, respectively. Fluorescence 
characteristics of BSNRs-RPV and BSNRs particles in 
cells were assessed by measuring the relative 
fluorescence emission intensity in MDM suspended in 
PBS. Fluorescence spectra of BSNRs-RPV in MDM 
showed a higher intensity compared to BSNRs. 
However, both particles were taken up in MDM, and 
fluorescence intensity correlated with the 
concentration of particles (Supplementary Figure 
S10D). We hypothesized that with treatment with 
BSNRs-RPV particles, uptake and retention of 
bismuth in MDM would correlate with the amount of 
drug (RPV) taken up and retained by the cells. Figure 
2B shows the two-parameter Pearson’s correlation 
between bismuth and RPV cell concentration for 
uptake (top) and retention (bottom). Comparisons 
were performed at each time point and the uptake of 
bismuth positively correlated with the uptake of RPV, 
with an “r” value of 0.9690. For retention, the 
correlation between bismuth and RPV was lower (r = 
0.8093), most likely due to the longer period of time 
over which the cells were analyzed (details for the in 
vitro correlation study are available in the 
supplementary results SR3 and Figure S9).  
To qualitatively examine the intracellular uptake 
of BSNRs-RPV particles and the microstructure of the 
cells, we added 25 μg/mL of BSNRs-RPV particles to 
MDM for 8 hours, collected the cells and fixed them in 
a fixative buffer.[24, 35] Nanoparticle loaded cells 
were examined by confocal microscopy (Figure 2C), 
TEM (Figure 2D), and validated by NIR fluorescence 
using NIR microscopy (Figure 2E). TEM images show 
BSNR particles endocytosed by MDM with higher 
magnification showing large numbers of BSNRs-RPV 
particles in vesicles, observed as black clusters 
distributed within lysosomes and other microvesicles 
(Figure 2D). These results were confirmed by 
May-Grünwald Giemsa staining that showed particles 
in the cells clearly visible by light microscopy 
(Supplementary Figure S10A-C). We assessed the 
surface topography of treated cells by AFM to 
determine characteristic morphological changes 
compared to control cells. BSNRs treated 
macrophages displayed a surface pseudopodium like 
morphology compared to control cells. AFM results 
demonstrated that particles were taken up in the cells 
with a slight change in cell surface morphology 
(Figure 2F).  
Antiretroviral activity was assessed in MDM to 
determine the activity of BSNRs-RPV and NRPV 
particles. Cells were pre-treated with 12 or 25 μg/mL 
of NRPV and BSNRs-RPV for 8 hours before being 
challenged with HIV-1ADA, a macrophage tropic 
strain,  at days 1, 3, 5 and 8 after treatment. Ten days 
after infection, culture supernatants were collected 
and HIV-1 reverse transcriptase (RT) activity was 
assessed as a measure of viral replication 
(Supplementary Figure S11). The remaining cells 
were fixed and HIV-1 p24 staining was used as a 
qualitative measurement of viral infection (Figure 3). 
Treatment with 12.5 or 25 μg/mL of BSNRs-RPV 
showed a notable reduction in HIV-induced 
multinucleation of macrophages at days 1, 3, 5, and 8 
compared to positive control (HIV infected 
macrophages). These results paralleled RT activity 
measurements while demonstrating comparable 
antiretroviral responses for NRPV. The antiretroviral 
activity of BSNRs-RPV (98% HIV-1 inhibition) was 
similar to that of NRPV (98% viral inhibition) after 8 
days of infection without any apparent difference of 
the BSNRs-RPV concentrations.  
Biodistribution and cellular localization of 
particles by SPECT, LA-ICP-MS and TEM 
imaging  
Our laboratory has been developing a 
theranostic, nanoparticle-based imaging platform that 
can be used to predict the long-term biodistribution of 
these medications by use of MRI and SPECT imaging 
early in the treatment regimen.[24, 33, 35] We 
hypothesized that a rod-shaped nanoparticle (termed 
“nanorods”) approximately the same size as our 
long-acting RPV nanocrystals, created from safe, 
(bismuth and sulfur) non-toxic “green elements”[36] 
could serve as an accurate predictor of RPV long-term 
biodistribution by intrinsically doping the BNSRs 
with 177Lu, a gamma-emitting radioisotope. If 
successful, a theranostic imaging platform would 
allow the creation of a data library to predict drug 
biodistribution in patients with greater precision than 
Theranostics 2020, Vol. 10, Issue 2 
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traditional PK and biodistribution analysis without 
the need for invasive and experiment ending isolation 
of tissue samples. 
 
 
Figure 1. Synthesis and characterization of multimodal particles. Uniform rod shaped BSNRs were made by a modified solvothermal method in the presence of 
oleylamine and oleic acid.[26, 28, 29] Oleylamine was the solvent for thioacetamide in forming the BSNRs (Supplementary Figure S1). Low-resolution TEM images of BSNRs 
are illustrated in (A). The BSNRs dimensions were approximately 12 nm in diameter by 70 nm in length. High-resolution TEM images of twin BSNR particles with lattice planes 
are shown in (B) with corresponding electron diffraction patterns. These are illustrated through the drawing of [4 3 1] and [1 3 0] space groups in the vector directions (C). The 
selected area electron diffraction (SAED) pattern of BSNRs are shown by simulation indexation. The indexation-detected lines correspond to characteristic interplanar spacing 
of the BSNR’s single crystal structure in (D). The bismuth (red) and sulfur (green) element mapping showed element localization within the particles by corresponding high-angle 
annular dark-field electron microscopy in (E). XRD patterns, correlations with HR- TEM, SAED and simulated data sets confirmed the particle’s structural configurations (F left 
panel). Quantitative measurements of particle element distribution were made by energy dispersive X-ray spectroscopy (F right panel). The hydrophobic and hydrophilic 
properties of the lipid coated particles are shown in the inset. The vial BSNRs were dispersed in cyclohexane. The vials contain mixtures of cyclohexane. The third vial shown 
illustrates the BSNRs particle hydrophilic properties produced by lipid coatings. These were dispersed in water. The schematic diagram of the particle’s configuration is shown 
on the vial top. The hydrodynamic size distribution of lipid-coated drug loaded particles as determined by DLS was compared against NRPV (G left panel). Excitation and emission 
spectra of BSNRs (g middle panel) are illustrated. BSNRs NIR fluorescence imaging is shown (G right panel). Chemical composition of BSNRs was assessed by X-ray fluorescence 
and demonstrated the following; Bismuth = 88.61 mass% and sulfur = 11.38 mass% contents (Supplementary figure S3) 
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Figure 2. Human macrophage particle uptake and retention. Human monocyte-derived macrophage uptake and retention of lipid-coated RPV loaded BSNRs were 
determined at two treatment concentrations (12.5 and 25 µg/mL as bismuth content) (A). Bismuth and RPV content were determined by ICP-MS and UPLC-MS/MS analysis, 
respectively. Pearson’s correlations of average bismuth and RPV content over time for both uptake and retention were determined (B). These served as a cross-validation of the 
drug loaded particle integrity in cells over the time periods used for analysis, presented in supplementary figure S9). To qualitatively determine cell uptake, macrophages were 
treated with 25 µg/mL of the BSNRs particles (25 µg/mL) for 8 hours and confocal (C), TEM (D) and NIR (E) cell images were obtained. The surface morphology of particle-loaded 
cells was assessed by AFM (F). Statistical differences were determined using two-way ANOVA between groups with a Bonferroni’s post hoc-test to correct for multiple 
comparisons. ***p < 0.001; ****p < 0.0001. 
 
We assessed the effectiveness of 177LuBSNRs 
particles as multimodal contrast agents for 
non-invasive real time imaging of biodistribution to 
the lymphoid organs in Balb/c mice. Biodistribution 
of 177LuBSNRs was investigated by SEPCT/CT at 6, 
12, 24, 48, and 120 hours after IV injection, as shown in 
Figure 4. Three-dimensional image reconstruction 
and autoradiographic counts were performed in 
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excised livers and spleens at days 2 and 5 (48 and 120 
hours, respectively). Quantitative studies were 
performed by measuring radioactivity by gamma 
scintillation spectrometry and by SPECT 
three-dimensional images to draw regions of interest 
(ROIs) and obtain counts per unit volume of tissue. 
The three-dimensional rendered SEPCT/CT images 
of the thoracic duct (cisterna chyli), liver, spleen, gut 
and lymph nodes are illustrated in Figure 4A and B 
(coronal and sagittal views, respectively), and 
illustrate the transition of 177LuBSNRs from the liver 
to lymph nodes over the 120 hour period. In the early 
time points high deposition of 177LuBSNRs in liver 
and spleen was observed. Radioactive signals in liver 
decreased steadily over time, with less than half of the 
radioactivity remaining by 120 hours. A strong signal 
was observed in spleen within 6 hours which 
increased over time. After 12 hours, 177LuBSNRs were 
readily observed in the gut and lymph nodes, in 
addition to liver and spleen. (Figure 4A-B and 
supplementary video files SV1-SV5;6 to 120 hours 
time points). At 24 hours post injection, 177LuBSNRs 
were deposited largely in spleen and were diminished 
in the liver. Importantly, 120 hours after particle 
administration, the particles were highly retained in 
the spleen while minimal levels were found in the 
liver (autoradiography results Figure 4C). Particle 
levels in the lymph nodes remained constant from 12 
to 120 hours. Ex vivo gamma scintillation examination 
was used to quantify radioactivity in liver, spleen and 
lymph nodes. Values of radioactivity in spleen were 
258 ± 9 and 337 ± 21 %ID/g at 48 and 120 hours, 
respectively. In contrast, liver radioactivity was 84 ± 8 
and 63 ± 8 %ID/g at 48 and 120 hours, respectively 
(Figure 4D). Radioactivity in axillary and inguinal 
lymph nodes remained constant between the two time 
points (Figure 4D left panel). This data was 
confirmed by 3D ROIs from SPECT images (Figure 
4D right panel). Even after 120 hours, no SPECT 
signal was found in the bladder, demonstrating the 
stability of 177LuBSNRs in vivo. The distribution of the 
177LuBSNRs in the liver and spleen at 48 and 120 hours 
was heterogeneous as illustrated by ex vivo 
autoradiography (Figure 4C). In the spleen, high 
particle numbers accumulated in the red pulp with 
limited accumulation in the white pulp.  
The utility of BSNRs particles as in vivo X‐ray CT 
contrast agents was also demonstrated using the 
newer technique of small animal radiation research 
platform (SARRP) (Xstrahl, Inc.) as illustrated and 
cited in supplementary Figure S14.[37] 
Cellular distribution of the particles in the spleen 
was investigated by laser ablation inductively 
coupled plasma mass spectrometry (LA-ICP-MS) 
imaging. Schematic representation of preparation of 
in vitro phantoms using chicken breast homogenates 
mixed with particles and creation of the calibration 
curve from matched matrix is shown in Figure 5A. 
 
Figure 3. Antiretroviral activities. Antiretroviral activity was determined in macrophages treated for 8 hours with NRPV and BSNRs-RPV particles (12.5 and 25 µg/mL), and 
then infected with HIV-1ADA at a multiplicity of infection (MOI) of 0.1 infectious particles per cell at days 1, 3, 5, or 8 after drug loading. At 10 days after infection, progeny HIV virion 
production was determined by P24 staining of cells. Antiretroviral activity was comparable for BSNRs-RPV and NRPV. Results for associated HIV RT activity in cell culture medium 
are available in supplementary figure S11. 
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The BSNR particles demonstrated very high spatial 
resolution, sensitivity and low limits of detection 
(LOD) close to 0.001 ppm in chicken breast tissue 
homogenates (Figure 5B and supplementary Figure 
S15-16). Spleen tissues prepared using this approach 
met the requirements of LA-ICP-MS analysis.[38] The 
BSNRs particles ex-vivo cellular distribution in spleen 
using LA-ICP-MS imaging of the bismuth signal 
showed a heterogeneous distribution pattern of the 
particles (Figure 5C, D). The results indicated that 
BSNRs and BSNRs-RPV particles deposited in the 
spleen to a higher extent on day 5 compared to day 2. 
Furthermore, distribution of particle patterns in the 
marginal zones of the spleen was much higher 
compared to distribution in white and red pulp. 
Quantitative analysis of the images demonstrated that 
the primary site of accumulation for particles is in the 
marginal zones where the maximum number of 
macrophages are located (Figure 5D, lower left 
panel). Particles also distributed to the red and white 
pulp, but to a lesser degree. BSNRs and BSNRs-RPV 
were uniformly distributed in matrix-matched spleen 
samples without aggregation (Figure 5D, lower right 
panel). We hypothesized that the particles would be 
taken up and sequestered by macrophages in tissues 
leading to particle depot formation that would allow 
slow release of therapeutic amounts of particles over 
time. To test our hypothesis, we injected mice 
intravenously with BSNRs (G6) and prepared liver 
and spleen sections for TEM imaging at days 2 and 5 
(Figure 6). Macrophages containing BSNRs could 
readily be found with a black aggregate in liver and 
spleen at days 2 and 5 (Figure 6, Row I). At higher 
magnifications, macrophages show large amounts of 
intracellular BSNRs particles (Figure 6, Row II).  
Increasing magnifications to 5x that of row II 
allowed validation of particle deposition in 
macrophages with clear visualization of individual 
BSNRs, and clusters of BSNRs within cells (Figure 6, 
Row III). The fact that BSNRs in cells appear to 
cluster, suggests the particles are taken up by 
endosomal vesicles in a similar manner to that 
observed with other nanoparticle platforms.[24, 35]  
Tissue drug and metal analysis profile  
To determine whether 177LuBSNRs particles 
could provide an accurate estimate of the long-term 
biodistribution of long-acting antiretroviral 
medications, we compared the distribution of BSNR 
particles to that of NRPV as a model long-acting 
medication. As shown in Figure 7A, male Balb/c mice 
received a single intravenous injection of either 
therapeutic particles (NRPV) or imaging particles 
(BSNRs) at various doses and in combination. The 
biodistribution of the different particles was assessed 
at various times post-injection using in vivo SPECT 
imaging and ex vivo ICP-MS and UPLC-MS/MS 
analyses for metal and drug content in tissues and 
plasma. Additionally, in vivo SPECT and LA-ICP-MS 
imaging results were complemented by measuring 
radioactivity in excised tissue samples of treated mice 
by gamma scintillation analysis and autoradiography. 
The various treatment groups are shown in Figure 7B. 
Table 3 displays the analytical technique used to 
measure each parameter for every group and at what 
time point each parameter was measured. In brief, the 
UPLC-MS/MS results for RPV content in tissues for 
groups treated with NRPV or BSNRs-RPV are shown 
in Figure 7C.  
The levels of RPV in liver were similar for 
animals treated with a high dose (45 mg/kg) of NRPV 
alone (G1) or in combination with BSNRs (G3). After 
two days, the RPV content in livers from G1 animals 
was approximately 6883.2 ± 4074.54 ng/g. By day 5 
the liver RPV concentration decreased to 317.2 ± 61.15 
ng/g. By the end of the study, 28 days after injection, 
21.3 ± 5.7 ng/g RPV remained in the livers of G1 
animals. RPV content in the livers of G3 (BSNR plus 
NRPV) animals showed a similar pattern with RPV 
content of 10,033.6 ± 1344.96 ng/g, 291.7 ± 93.28 ng/g, 
and 25.0 ±1.7 ng/g for days 2, 5, and 28, respectively. 
The pattern of RPV concentration over time in the 
livers of animals treated with a lower dose (5 mg/kg) 
of NRPV (G2) or BSNRs-RPV (G4) was also similar. 
G2 livers contained 139.9 ± 37.9, 26.8 ± 2.6, and 2.1 ± 
0.55 ng/g RPV on days 2, 5, and 28, respectively. RPV 
content in G4 livers was lower than that of G2 livers at 
19.7 ± 15.6, 1.6 ± 0.35, and 1.3 ± 0.67 ng/g RPV on days 
2, 5, and 28, respectively, but the trend over time was 
similar. 
Table 3. Real time iv vivo drug biodistribution measurement by design of multimodal theranostic and therapeutic nanoparticle study. 
Groups Formulations In vivo test 
Dose mg/kg SEPCT/CT Gamma Counter UPLC-MS/MS ICP-MS 
RPV Bi Time (hour) Time (day) Time (day) Time (day) 
G1 NRPV-High 45 -- -- -- 1,2,3,5,7,14,21,28  
G2 NRPV-Low 5 -- -- -- 1,2,3,5,7,14,21,28  
G3 BSNRs + NRPV 45 80 -- -- 2,5,28 2,5,28 
G4 BSNRs-PRV 5 80 -- -- 2,5,28 2,5,28 
G5 177LuBSNRs ~1000 
µCi 
~80 6,12,24,48, 120 2, 5 -- -- 
G6 BSNRs -- 80 -- -- -- 2,5,28 
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Figure 4. Real time biodistribution of multimodal particles in mouse tissues. SPECT imaging was used to assess distribution of intrinsically labeled 177LuBSNRs. 
177LuBSNRs particles (177Lu = ~1000 μCi, particle size of ~ 200 nm based on DLS) were injected intravenously into Balb/c mice. Whole body coronal SPECT/CT images were 
collected at 6, 12, 24, 48 and 120 hours after injection (A). Corresponding sagittal images are also shown (B). 177Lu radioactivity intensity is reflected by the colors shown. High 
signal intensity was detected in the lymph nodes (LN), liver, spleen and gastrointestinal (GI) tract tissues. Images were adjusted for an appropriate fitting with the tracer 
distribution. The ex-vivo autoradiography studies (C) show homogeneous accumulation of 177LuBSNRs in the liver tissue that decreases over time (48 hours > 120 hours). 
Breakdown of particles in liver could lead to free 177Lu absorption in bone, as seen near the lower spinal cord at later times. Accumulation of 177LuBSNRs in spleen showed a 
heterogeneous distribution pattern and increased particle concentrations over time (120 hours > 48 hours). Quantitative studies were done by measuring radioactivity by gamma 
scintillation spectrometry analysis (left) and SPECT 3D images were used to drawn ROIs (right) to obtain radioactivity counts per volume of tissue (D). Significant differences 
were determined using two-way ANOVA between groups followed by a Bonferroni’s post-hoc test to correct for multiple comparisons. *p < 0.05, ***p < 0.001; ****p < 0.0001. 
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Figure 5. Tissue particle localization by LA-ICP-MS. Schematic representation of preparation of in vitro phantoms using chicken breast homogenates mixed with BSNRs 
particles and creation of the calibration curve from matched matrix (A). Determination of spatial resolution, sensitivity and lower limit of detection (LOD) of BSNRs particles in 
breast homogenates tissues (B). Lower limit of bismuth detection analyzed by LA-ICP-MS by preparation of “phantom tissue” with particle mixture by using chicken breast tissues 
homogenate. Serial dilutions of particles plus tissues homogenate mixture were used to create a calibration curves from LA-ICP-MS imaging spots. Bismuth was detectable in 
tissue mimics at all calibration points. Fifty micrometer resolution is needed to properly observe subcellular distribution. Distribution of particles in spleen slices was determined 
on days 2 and 5 after injection of BSNRs and BSNRs-RPV particles in mice (C). The distribution of the particles in the spleen was monitored with high spatial resolution and 
sensitivity using LA-ICP-MS imaging. Bismuth signal in spleen sub regions after injection of particles (D) showed a heterogeneous distribution pattern. Higher distribution in the 
macrophage-rich marginal zone compared to white pulp and red pulp was observed (D). The uneven particle distribution pattern observed across the structural architecture of 
the spleen and confirmed by quantitative measurements by LA-ICP-MS can be explained by higher macrophage populations in marginal zone that are specialized for uptake and 
storage of particles. A two-way ANOVA between groups followed by a Bonferroni’s post-hoc test to correct for multiple comparisons was performed to determine statistical 
differences. ****p < 0.0001; n.s.= not significant. (Associated controls and additional experimental results analysis are presented in supplementary Figure S15-16) 
 
RPV concentrations in the spleens of G1 (NRPV 
45 mg/kg) animals were lower than those in liver on 
day 2 but higher on days 5 and 28 (Figure 7C). 
Concentrations were 5250.4 ± 3063 ng/g RPV on day 
2, 683.6 ± 221 ng/g RPV on day 5 and 42.5 ± 16.86 
ng/g RPV on day 28. For G3 (BSNR plus NRPV 
45mg/kg) animals, RPV concentrations in spleen 
were twice that of the liver RPV concentrations on all 
days with values of 22,020.1 ± 3971 ng/g RPV on day 
2, 569.2 ± 215.4 ng/g on day 5, and 67.7 ± 11.04 ng/g 
on day 28. RPV content in the spleens of G2 and G4 
animals, which received a lower dose of NRPV or 
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BSNRs-RPV, were similar to concentrations in 
autologous livers. For G2 spleens, RPV concentration 
was 189.2±64.5 ng/g on day 2, 24.4±3.8 ng/g on day 5, 
and 3.8±2.5 ng/g by day 28. Splenic RPV 
concentrations for G4 animals closely matched that 
observed for G2 animals with values of 138.8±121 
ng/g, 2.6±3.6 ng/g, and 6.71± 3.3 ng/g RPV on days 2, 
5, and 28, respectively. 
Concentration of RPV in the lymph nodes was 
less than that of liver and spleen, but followed a 
similar pattern over time as in those tissues (Figure 
7C). For G1 animals, RPV concentrations in the lymph 
nodes were 156.6 ± 31.6 ng/g RPV on day 2, 171.4 ± 
71.8 ng/g on day 5, and 50.9 ± 16.8 ng/g on day 28. 
Similar values were obtained from lymph nodes 
excised from G3 animals with RPV concentrations of 
160.9 ± 52.5 ng/g, 37.3 ± 12.4 ng/g, and 80.4 ± 37 ng/g 
on days 2, 5, and 28, respectively. RPV concentrations 
in lymph nodes of animals treated with the low dose 
of NRPV (G2) decreased over time with values of 22.8 
± 7.3 ng/g on day 2, 4.1 ± 3.8 ng/g on day 5, and 5.4 ± 
1.2 ng/g on day 28. However, the RPV content of 
lymph nodes from animals treated with RPV loaded 
BSNRs (BSNRs-RPV) was lower than that in G2 
animals on day 2 (7.1 ± 4.4 ng/g) and remained 
constant thereafter through day 28 (5.4 ± 1.8 ng/g). 
Bismuth concentrations in tissues over time from 
animals in G3 (BSNRs plus NRPV), G4 (BSNRs-RPV) 
and G6 (BSNRs only) were determined by ICP-MS 
analysis. The results for liver, spleen, lymph nodes, 
and kidneys are shown in Figure 7D and E. For G6 
animals, bismuth concentration in the liver increased 
significantly (P<0.05) from day 2 to day 5, from 183.3 
± 26.19 g/g to 237.2 ± 19.41 g/g and decreased 
slightly to 200.7 ± 17.88 g/g by day 28. Bismuth 
content in the livers of G3 animals showed a similar 
pattern with a significant increase in bismuth 
concentration from day 2 to day 5 (200.0 ± 26g/g 
bismuth to 246.7 ± 18.3 g/g bismuth) followed by a 
non-significant drop to 223.9 ± 19.3 g/g on day 28. 
Again, a similar pattern was observed in G4 livers in 
terms of bismuth concentration. On day 2, liver 
concentration was 181.9 ± 36.4 g/g bismuth followed 
by a significant accumulation by day 5 (251.6 ± 42 
g/g) and a non-significant decrease by day 28 (241.1 
± 13.7 g/g). 
 
 
Figure 6. Subcellular particle localization. TEM images were obtained for liver and spleen 2 and 5 days after injection of BSNRs particles (80 mg /kg bismuth). Panels (ii) and 
(iii) are higher-powered images from black color particles deposited regions by from panel (i). Presence of BSNRs particles (black dots) can be visualized in macrophages in both 
liver and spleen sections 
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The concentration of bismuth in spleens showed 
a pattern of non-significant accumulation between 
days 2 and 5, followed by a significant increase in 
concentration between days 5 and 28 for each of the 
three groups of animals that received BSNRs (G3, G4, 
and G6). The concentration of bismuth in G3 spleens 
increased from 72.4 ± 7.0 g/g to 117.4 ± 11.2 g/g 
from day 2 to day 5 and then further increased to 
137.8 ± 7.6g/g by day 28. For G4 spleens a similar 
pattern was observed, with a non-significant increase 
from 109.7 ± 4.9 g/g to 134.4 ± 4.8 g/g bismuth 
from day 2 to day 5 followed by a larger, significant 
increase to 170.6 ± 13.1 g/g by day 28. Bismuth 
concentration in G6 spleens followed the same pattern 
with measured values of 97.5 ± 10.3 g/g, 109.5 ± 13.7 
g/g, and 162 ± 13.1 g/g bismuth on days 2, 5, and 
28, respectively.  
Concentrations of bismuth in lymph nodes of 
G3, G4, and G6 animals were lower than that in the 
spleen and liver. However, lymph node 
concentrations of bismuth did not change 
significantly over the course of 28 days for any of the 
three groups. For G3, bismuth concentration in the 
lymph nodes on day 2 was 1.84 ± 0.001 g/g with 
concentrations on day 5 and day 28 of 0.89 ± 0.2 g/g 
and 0.35 ± 0.5 g/g, respectively. The bismuth 
concentration in the lymph nodes of G4 animals was 
similar to that in G3 animals with values of 0.88 ± 1.3 
g/g, 0.34 ± 0.07 g/g, and 0.64 ± 0.7 g/g on days 2, 
5, and 28, respectively. G6 animals received only 
BSNRs and the bismuth concentration in lymph nodes 
was 0.31 ± 0.3 g/g on day 2, 0.89 ± 0.7 g/g on day 5, 
and 0.36 ± 0.1 g/g, on day 28. Overall the 
concentration of bismuth in the lymph nodes of all 
animals remained relatively constant over the 4 weeks 
post-treatment. Bismuth concentration was also 
measured in the kidneys of G3, G4, and G6 animals by 
ICP-MS (Figure 7E, left panel). Again, all groups 
followed a similar pattern of Bismuth concentration 
over time. Between days 2 and 5, the concentration of 
bismuth changed non-significantly from 3.34 ± 0.35 
g/g to 3.65 ± 0.21 g/g, 4.35 ± 0.3 g/g to 2.82 ± 0.15 
g/g, and 6.17 ± 0.2 g/g to 9.24 ± 0.05 g/g for G3, 
G4, and G6 animals respectively. From day 5 to day 28 
all groups saw a significant accumulation of bismuth 
in the kidneys with concentrations of 9.60 ± 1.2 g/g, 
8.09 ± 1.07 g/g, and 9.24 ± 0.70 g/g for G3, G4, and 
G6, respectively. 
RPV concentrations were assessed over time for 
groups that received NRPV (G1, G2, G3) or 
BSNRs-RPV (G4) (Figure 7E, center and right panels). 
On day 1 RPV concentration in G1 plasma was 520.0 
ng/mL and declined rapidly to 76.7 ng/mL by day 7, 
then remained fairly constant until day 28 at 61.9 
ng/mL (Figure 7E, center panel). Plasma 
concentration of RPV in G3 animals followed a similar 
pattern over time. On day 1, RPV concentration in G3 
plasma was 1229.1 ng/mL and then decreased to 5.25 
ng/ml at day 7. From day 7 to day 28 there was a very 
slow decrease in plasma concentration to 1.4 ng/mL.  
For G2 animals, RPV concentration was 137.6 
ng/mL at day 1 and declined to 17.8 ng/mL by day 5 
(Figure 7E, right panel). From day 5 until day 28, 
plasma RPV concentration slowly declined to 10.8 
ng/mL. For G4 animals treated with BSNRs-RPV, 
plasma RPV concentration on day 1 was relatively 
low, 3.1 ng/mL, but increased to 18.4 ng/mL by day 
14. From day 14 to day 28 the plasma RPV 
concentration remained constant and on day 28 
plasma RPV was 10.2 ng/mL. These results suggest a 
slower release of RPV into the plasma from 
BSNRs-RPV than from NRPV alone, potentially 
prolonging its effects in the body. In vivo treatment 
with BSNRs, BSNRs-RPV, NRPV, and combinations 
of BSNRs plus NRPV produced no observed toxicity 
in liver, kidney, or pancreas as determined by serum 
chemistry and histological analysis results 
(Supplementary figures 20 and 21).  
Metadata analysis 
LA ARVs could overcome limitations in 
HIV/AIDS therapeutic regimens that limit optimal 
clinical outcomes.[14] The ability to sustain plasma 
and tissue drug levels beyond the plasma 90% 
inhibitory concentration (IC90) for months would 
reduce pill burdens, increase regimen adherence and 
reduce adverse events that plague current 
medications. This would also lift the psychological 
stigma for strict daily regimens reminding patients of 
disease and impacting mental health.[16, 39, 40] To 
simplify measurements of LA ARV efficacy by 
pharmacokinetic (PK) and biodistribution (BD) tests 
and optimize dosing, theranostics was introduced.[16] 
The traditional PK and biodistribution assessments 
which require end-point animal sacrifice and organ 
removal could be exchanged by bioimaging-based 
measurements.[24] To determine whether rod-shaped 
particles were reflective of the PK and biodistribution 
of LA NRPV, biodegradable BSNRs formulations 
were created. These newly synthesized particles were 
then deployed as a predictor of RPV long-term 
biodistribution. 177LuBSNRs were used as a 
theranostic imaging platform to compare six 
treatment regimens. After group data was acquired 
across time, predictive values were determined for 
particle drug biodistribution. Pearson’s correlation 
coefficients were calculated for group comparisons of 
RPV concentrations, bismuth concentrations, SPECT 
ROI (Supplementary figure S13), and gamma 
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scintillation counts from excised organs. Means of 
absolute “r” values with p ≤ 0.05 were used to create 
the “multiple ribbon bar graph” (Figure 8).  
 
 
Figure 7. BD and PK. A schematic representation of the nanoformulated therapeutic particles (NRPV) and multimodal imaging particles (BSNRs) is shown in (A). The type of 
treatment and particle size administered to mice, and analyses techniques used are illustrated. Treatment scheme for intravenous injection of high dose NRPV (G1) (45 mg/kg 
RPV), low dose NRPV (G2) (5 mg/kg RPV), BSNRs (80 mg/kg based on bismuth) plus NRPV (45 mg/kg RPV) (G3), BSNRs-RPV (80 mg/kg based on bismuth plus ~5 mg/kg RPV) 
(G4), 177LuBSNRs (37 MBq = ~1000 µCi = ~ 80 mg/kg based on bismuth) (G5) and plain BSNRs (80 mg/kg based on bismuth) in male Balb/cJ mice is shown in (B). RPV levels in 
liver, spleen, and lymph nodes 2, 5, and 28 days after treatment of mice with NRPV high and low dose, BSNRs plus NRPV and BSNRs- RPV were determined by UPLC-MS/MS 
(C). Bismuth contents in liver, spleen, lymph nodes and kidneys from mice treated with BSNRs and BSNRs plus NRPV and BSNRs-RPV were determined by ICP-MS from days 
2, 5, and 28 (D-E left side). Plasma RPV concentrations of mice treated with NRPV high and low dose, BSNRs plus NRPV and BSNRs- RPV were determined on days 1 through 
28 by UPLC-MS/MS. Statistical differences were determined using two-way ANOVA between groups. Multiple comparison correction was done using a Bonferroni’s post-hoc 
analysis. *p < 0.05 (p = 0.0256); ***p < 0.001; ****p < 0.0001; n.s.= not significant. 
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From imaging analyses, biodistribution and PK 
studies data for various parameters were measured in 
plasma and tissues for 6 treatment groups with the 
analysis parameter depending on the treatment 
(supplementary figure S12) as shown in Table 3. 
These parameters included RPV concentration 
(UPLC-MS/MS), bismuth concentration (ICP-MS), 
SPECT signal, and gamma counts for excised organs. 
To assess the predictive value of the BSNRs to 
estimate long-term biodistribution of LA ARVs such 
as NRPV, we used Pearson’s correlation analysis for 2 
parameter comparison on averaged data collected 
from different groups on the same day. Correlation 
“r” values were generated for each comparison and 
statistically significant correlations with r > 0.5 were 
plotted. For same day comparisons in the liver, the 
highest degree of correlation was between RPV and 
bismuth on day 2 (r = 0.9796). Additionally, G1 RPV 
concentration in the liver correlated significantly with 
bismuth concentration in G4 animals treated with 
BSNRs-RPV (r = 0.9412). Interestingly, the lower dose 
of NRPV (G2) correlated extremely well with our 
BSNRs-RPV (G4) in terms of RPV concentration even 
to 28 day with r = 0.8536. These data demonstrated 
that RPV loaded BSNRs reflected the biodistribution 
of NRPV. Gamma scintillation analysis of G5 livers 
excised 5 days post-treatment correlated with bismuth 
concentration (r = 0.9005). Furthermore, gamma 
counts of excised day 5 livers correlated with RPV 
concentration on the same day (r = 0.8264). Most 
importantly, we observed that SPECT signal and RPV 
concentration on day 5 were strongly correlated (r = 
0.8676). In spleen, RPV concentration (G2) correlated 
with bismuth concentration, gamma scintillation 
counts, and SPECT signal (r = 0.9412, 0.8361, and 
0.5593, respectively). SPECT signal (G5) in spleen also 
significantly correlated with bismuth concentration 
on day 2 (r = 0.8993) for animals treated with 
BSNRs-RPV (G4). In lymph nodes, SPECT signal (G5) 
correlated with RPV concentration on day 2 from 
multiple groups including G1, G2, and G3 with r = 
0.5259, 0.5416, and 0.6936, respectively 
(Supplementary figure 19 graphs A, C and E). We 
observed an even stronger correlation between SPECT 
signal (G5) and RPV concentration (G2) on day 5 (r = 
0.9278) (Supplementary figure 19 graph D). Day 5 
lymph node SPECT signal also correlated with 
bismuth concentration (r = 0.7283), providing 
evidence that the SPECT signal could be used to 
predict RPV concentration in vivo. Gamma 
scintillation counting was also closely associated with 
bismuth and SPECT signal (r = 0.8545 and 0.9731 
respectively).  
The data, in toto, demonstrates that SPECT signal 
reflects RPV drug concentrations. We also looked at 
the associations between various different data 
combinations (e.g., RPV vs Bismuth) acquired at 
different times to determine the predictive value of 
the BSNRs platform. In the lymph nodes, we observed 
that SPECT signal at 2 days post-treatment was 
predictive for RPV concentration on day 28, for both 
high dose NRPV group (G1) and RPV-BSNRs (G4) 
with strong correlation values (r = 0.7709 and 0.7830, 
respectively). SPECT signal from day 2 was also 
predictive for day 28 bismuth concentration in the 
lymph node (r = 0.7643). In the spleen, SPECT signal 
from days 2 and 5 could be predict bismuth 
concentration on day 28 (r = 0.9255 and 0.9044, 
respectively), while day 2 bismuth concentrations 
correlated with day 28 RPV concentration (r = 0.987). 
In liver, gamma scintillation counts from day 5 
provided the best correlative values in terms of RPV 
and bismuth content on day 28. Day 5 gamma 
scintillation counts correlated with RPV 
concentrations from G1, G2, and G3 (r = 0.8591, 
0.9142, and 0.6801, respectively). Group correlations 
for spleen parameters were also determined and are 
illustrated in supplementary figures S17-19. Overall 
the correlative data obtained from the tissues 
provides evidence that bioimaging by SPECT 
accurately predicts LA RPV drug levels in lymphoid 
tissues. 
Discussion  
While drug-encased theranostic nanoparticles 
are developed for cancer and inflammatory disease 
[41-44] little has yet to be achieved for HIV 
diagnostics and treatments. Thus, an immediate need 
warrants the creation of theranostic ARV particles 
optimized for size, shape, and structure to ensure 
proper distribution to CD4+T cells and macrophages. 
All will ensure improved PK as the drug’s apparent 
half-life is extended. To achieve these goals and to 
simplify assessments of LA ART for PK, 
biodistribution and dosing theranostics was 
employed. Traditional PK requires end-point animal 
sacrifice and organ removal. These we posit can be 
exchanged by bioimaging tests. To determine whether 
rod-shaped particles are reflective of LA RPV size and 
shape and as such could predict drug biodistribution 
biodegradable bismuth and sulfur formulations were 
created. We assessed, in real time, the biodistribution 
of drug loaded multimodal radiolabeled particles 
(177LuBSNRs) and used them to predict LA RPV 
pharmacological properties. The BSNRs-RPV particles 
were used successfully to determine ARV 
effectiveness through measures of drug distribution 
into HIV tissue and cell reservoirs by noninvasive 
measurements.  
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Figure 8. Multiplex statistical data analyses. Pearson’s correlation coefficients metadata were generated from SPECT, UPLC-MS/MS (RPV), ICP-MS (Bismuth) and gamma 
scintillation analysis of liver (A), spleen (B), lymph node tissues (C). Key components calculated across groups with fitting Pearson’s correlation coefficients using a p-value ≤ 0.05 
are shown as multiplane ribbon plots (Supplementary Figure S17-19). 
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Over the past two decades our laboratories 
investigated the role of particle size and shape for 
their distribution.[24, 35, 45-47] The results showed 
that rod-shaped nanoparticles were efficient and 
rapidly taken up in macrophages.[33, 48-50] The 
combinatorial effect of particle size and shape reflects 
Fc receptor mediated macrophage engulfment and 
internalization. Indeed, nanoformulations with a rod 
shape were known to be taken up by macrophages at 
faster rates than spherical particles.[48] Indeed, prior 
research into the shape of mesoporous silica 
nanoparticles demonstrated that those particles with 
larger aspect ratios were internalized faster.[51] These 
results supported other previously published 
reports.[52, 53] Based on need coupled with prior 
studies demonstrating a “rod-like” particle shape is 
an efficient entry into macrophages as the principal 
depot, we developed theranostic ARV formulations to 
reflect the shapes of native LA drugs.[54-57] 
Moreover, coating the surface of nanoparticles with 
polyethylene glycol (PEG), termed “PEGylation”, was 
shown to improve the efficiency of drug and gene 
delivery.[58, 59] Firstly, PEGylation reduces 
aggregation of particles by diminishing the 
association with nontargeted serum and tissue 
proteins and resulting `stealth' behavior.[60] The PEG 
polymers reduces charge-based contact typical of 
proteins and small-molecule interactions.[61] Second, 
PEGylation increases the circulation time of 
nanoparticles by preventing non-specific uptake by 
the liver and spleen.[62] Third, PEGylated 
nanoparticles have increased solubility in buffer and 
serum due to the hydrophilic ethylene glycol repeats. 
Fourth, PEGylation reduces systemic and cellular 
toxicities of nanoparticles.[63] In all, these properties 
underlie the properties of the PEG polymer formed by 
repeating ethylene glycol monomers. PEG polymers 
of varying lengths exist and some reports number of 
ethylene glycol monomers in a chain of up to 40. PEG 
molecular weights are up to 20,000 Da and the 
thickness of any grafted PEG correlates with its 
molecular weight and density as present on the 
nanoparticle surface.[64] In our studies, using 
PEG2000 was enough to consistently generate 
nanorods of the same size as our nanoformulated 
RPV. PEGylation also results in a tighter size 
distribution of produced particles by decreasing 
aggregation. In terms of increasing therapeutic 
efficacy, PEG coatings increase the circulation half-life 
of nanoparticles but also improve the penetration of 
particles into “biological barriers”, including reducing 
interactions with tissue extracellular matrix, cellular 
barriers, and biological fluids such as mucus, 
especially when delivering poorly water-soluble 
drugs.[65, 66] Overall, it is a combination of the 
density of PEG polymers and the number of 
polyethylene glycol repeats/polymer that affect 
therapeutic efficacy and particle size.  
LA ART is a means to overcome limitations in 
HIV therapeutic regimens that often preclude best 
clinical outcomes.[14-16, 67] The ability to sustain 
plasma and tissue drug levels above effective plasma 
concentrations for months would have a real impact 
on the care and prevention of viral infection. 
Moreover, it would reduce pill burden, increase 
regimen adherence, and limit adverse events that 
plague current drug regimens. This would also lift the 
stigma for strict daily regimens that remind patients 
of their disease.[16, 39, 40]  
As a result, we hypothesized that BSNRs with a 
clear-cut, rod shape morphology that matches the 
shape and size of our long acting nanoformulated 
therapeutic drug nanoparticles provide a platform to 
accurately and efficiently predict long-term 
therapeutic drug biodistribution and that these tests 
could be performed by SPECT and LA-ICP-MS. To 
achieve this goal, theranostic particles were made of 
identical size and morphology (“rod-shaped”) as LA 
ARVs that are used currently in phase III treatment 
paradigms.[68] This was achieved in step-wise 
fashion. First, we created lipid coated 177LuBSNRs as a 
multimodal imaging particle for non-invasive and 
real-time imaging. Second, LA RPV (NRPV) was 
deployed to model drug biodistribution. Imaging 
enabled particle tracking in real time and specifically 
tracked the distribution into “putative” tissue 
reservoirs of infectious virus. Third, the particles 
allowed direct and real-time visualization for the 
abilities of drug to distribute to lymphoid organs. 
Fourth, state of the art characterizations that included 
surface modification of imaging particles with a thin 
lipid layer provided high cell uptake and aqueous 
solubility, biocompatibility and stability. Fifth, 
cell-based experiments demonstrated rapid particle 
uptake, retention, and antiretroviral efficacy in target 
macrophages. Particle uptake remained constant from 
4 to 8 hours possiblely due to cells reaching their 
capacity or exocytosis at later times. Macrophages 
rapidly internalized rod-shaped nanoparticles 
compared to spherical particles.[48, 69, 70] Because 
the uptake mechanism used by the macrophages was 
phagocytosis, shape, size, surface properties as well as 
quantity of particles played a significant part in 
uptake.[48, 50, 69, 70] The eight days of antiretroviral 
efficacy exhibited by BSNR-RPV accords with similar 
studies that found between 5 and 20 days of 
protection with NRPV.[71] Provided that on average 
more than 1 microgram was retained per million cells, 
which positively correlated with bismuth intracellular 
concentrations, it can be surmised that RPV depots 
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were maintained until our assay’s terminus. 
Numerous reports characterize RPV's potency in the 
sub-nanomolar range. [71, 72] Therefore, the 
equivalent levels of long-term protection regardless of 
treatment concentration in our work may be 
explained in that macrophages treated with low- and 
high-dose BSNR-RPV maintained drug 
concentrations above RPV's 50% maximal effective 
concentration (EC50) for at least eight days. Sixth, 
particles’ use as a multi-modality agent was 
confirmed by both SPECT, LA-ICP-MS, ICP-MS and 
UPLC-MS/MS in mice. Such imaging allowed, for the 
first time, sub-organ localizations in live animals with 
a high degree of sensitivity and specificity, exceeding 
those acquired by conventional magnetic resonance 
imaging (MRI).  
In recent years, the development of bismuth 
nanorods, nanoparticles, nanodots, and nanoplates 
has been described for a wide range of biomedical and 
bioimaging applications.[28, 73, 74] These include 
therapeutics and drug delivery for metabolic, 
inflammatory, and cancerous diseases and use as 
biosensors, photothermal and contrast agents.[75-78] 
While the field of BSNRs theranostics remains in its 
infancy, the primary challenge in next step 
applications rests in enhancing radiolabeling 
efficiency and drug loading. Notably, 
non-radiolabeled BSNRs have been successfully used 
as imaging agents as “bismuth” has an ultrahigh 
X-ray attenuation coefficient (bismuth, 5.74 cm2/g−1 at 
100 keV).[27, 79] High blood and renal concentrations 
of bismuth ions are considered safe.[80-83] Bismuth is 
considered one of the most biocompatible metals 
having been widely employed as an anti-diarrheal 
(bismuth subsalicylate); an antimicrobial (for 
eradication Helicobacter pylori, Pseudomonas aeruginosa, 
Burkholderia multivorans and B. cenocepacia); and as an 
antidote for cadmium poisoning.[84] The precursor 
chemicals of BSNRs synthesis are comparatively 
inexpensive compared to other metals, such as gold 
and platinum.[85] Bismuth and sulfur components 
easily undergo oxidative decomposition to soluble 
bismuth (III) species under physiological conditions 
and show considerable lipophilicity and membrane 
permeability, as such, differ substantively from other 
metal particles.[86, 87] Our results demonstrate that 
particle shape influences particle distribution in 
regional zones of spleen. This indicates that 
177LuBSNRs readily accumulate in lymphoid organs, 
including gut, indicating the rapid migration and 
deposition of particles in these organs where 
maximum number of HIV-1 are present. This 
observation matched SPECT results that indicated 
highly particle uptake and deposition in tissues with 
large numbers of macrophages and other immune 
cells. Such multifunctional imaging (177LuBSNRs) and 
therapeutic particles (NRPV) will facilitate rapid 
screening of antiviral drug tissue distribution.  
Each imaging technology that was or can be 
employed in future research has its own inherent 
limitations.[88] Information attained from single 
imaging modality tracking nanoparticles typically 
cannot satisfy the requirement to directly visualize 
infection sites and quantify the amount of drug at 
those sites. Hence, combination of more than two 
imaging modalities into a single particle, known as an 
“all-in-one” nanostructure, allows for spatial 
temporal assessments of virus replication sites. SPECT 
generates real-time, high-resolution 3D 
reconstructions.[89, 90] The SPECT bimodality 
imaging of lymphoid organs with 
lipid/calcium/phosphate (LCP) nanoparticles grafted 
with 111In has been reported.[91] Similarly, recent 
reports demonstrate that bismuth nanocrystals 
encapsulated in PLGA particles can be used 
effectively as a CT contrast agent.[92] Lipid coating on 
the BSNRs facilitates such use as it prevents 
aggregation in physiologic conditions.[93-95] 
Considering these advantages, SPECT imaging 
through radiolabeled BSNRs allows direct 
visualization of tissue sites of viral replication, 
providing a notable advantage for finding where 
residual virus may hide from immune surveillance 
mechanisms.[96, 97, 98] Interestingly, BSNRs 
concentrations were found in spleen at higher levels 
than in the liver. The extensive metabolism in liver 
may facilitate more rapid organ clearance for BSNRs 
compared to spleen.[99] Finally, the decomposition of 
BSNRs in liver due to plasma proteins on the surface 
of particles may also facilitate clearance.[100, 101]  
Liver metabolism of our BSNRs particles could 
result in the leaching of particle components that 
include free 177Lu. This concern coupled with signals 
observed in or near bones plates in later evaluated 
time points could affect experimental results. [102] 
Nonetheless, we affirmed the specificity of the SPECT 
data as popliteal and axillary lymph nodes and bone 
were independently dissected and subjected to 
gamma scintillation analysis. These data sets further 
confirmed the SPECT specifically and both assays 
were concordant. Thus, while release of 177Lu ions 
may occur its effects on the overall interpretation of 
particle-drug biodistribution is limited. 
Our analyses revealed that BSNR-RPVs could 
serve as a predictor for RPV drug levels and 
effectiveness. In fact, 5 days after injection, SPECT 
signal and RPV concentration were correlated 
strongly, one with the other (r = 0.8676). In spleen, 
RPV correlated with bismuth concentration, gamma 
scintillation counts, and SPECT signal (r = 0.9412, 
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0.8361, and 0.5593, respectively). In lymph nodes, 
SPECT signal correlated with RPV concentration on 
day 2 (r = 0.6936). We observed an even stronger 
correlation between SPECT signal and RPV 
concentration on day 5 (r = 0.9278). Day 5 lymph node 
SPECT signal also correlated with bismuth 
concentration (r = 0.7283), providing evidence that the 
SPECT signal could be used to predict RPV or 
bismuth biodistribution in a treated animal. 
LA-ICP-MS imaging is a powerful tool for 
providing sub-organ distribution information, 
enabling greater insight into the biological fate of 
nanoparticles. The quantitative capability of such 
imaging assays also facilitates delivery optimization 
by providing comparative formulation metrics.[103, 
104, 105] The use of laser ablation allows monitoring 
of each tissue type with resolutions between 25 to 50 
µm demonstrating cell nanoparticle distributions. 
When properly configured, LA-ICP-MS can image the 
distributions of nanoparticles with core diameters of 2 
nm present at low parts-per-billion 
concentrations.[106] Because bismuth has a very low 
biological background, the BSNRs are an almost ideal 
nanomaterial for fully exploiting the resolution 
capabilities of LA-ICP-MS.  
In conclusion, we have demonstrated the 
feasibility of theranostics for studies of LA ARV 
biodistribution and activity. Using both SPECT and 
LA-ICP-MS analyses 177LuBSNRs were shown to be a 
viable tool to monitor the distribution and transport 
or ARVs and in particular RPV to macrophage rich 
lymphoid tissues and liver. The PK and 
biodistribution patterns obtained with particle are 
comparable to therapeutic particles now being 
employed in treatment paradigms for HIV-1 
infection.[24, 33] Moreover, the results were cross 
validated by statistical models providing a framework 
for predictive assessments of LA ARVs distribution 
and activities in an infected human host. 
Experimental section 
Reagents and chemicals 
Bismuth neodecanoate (Bi(OCOC(CH3)2(CH2)5 
CH3)3), thioacetamide (CH3CSNH2), oleic acid, 
oleylamine, L--phosphatidylcholine (PC) (from egg 
yolk), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), were obtained from Sigma 
Aldrich, St. Louis, MO, USA. Corden Pharma 
International (Plankstadt, Germany) supplied the 
1,20-distearoyl-phosphatidylethanolaminemethyl- 
polyethyleneglycol conjugate 2000 (DSPE-PEG2000). 
Hangzhou Bingo Chemical Co., Ltd. (Hangzhou, ZJ, 
China) provided the rilpivirine (RPV). Lutetium (III) 
chloride, anhydrous, 99.9% (LuCl3) was received from 
Alfa Aesar, Haverhill, MA, USA. 177Lutetium chloride 
(177LuCl3) in 0.05 M HCl, mass = 3.0 µg was requested 
and delivered from Oak Ridge National Laboratory, 
Oak Ridge, TN, USA. Pluronic F 108 Pastille (P338) 
was bought from BASF, Florham Park, NJ, USA. 
Agilent Technologies, (Santa Clara, CA, USA) was the 
source of the monoclonal mouse HIV-1 p24 (Clone 
Kal-1) and Dako EnVision+ detection system HRP 
labeled polymer anti-mouse antibodies used in this 
paper. [33, 35, 71] Leukapheresis was performed on 
HIV-1,2 and hepatitis B seronegative donors and 
human peripheral blood monocytes were obtained 
and purified by countercurrent centrifugal elutriation. 
Monocytes were differentiated into macrophages 
according to our previously published protocols. [24, 
35, 33, 71] 
Animals 
Male Balb/cJ mice (6-7 weeks old) were 
purchased from Jackson Laboratories (Bar Harbor, 
Maine, USA). Animals were housed in the University 
of Nebraska Medical Center (UNMC) Comparative 
Medicine animal facility according to the Association 
for Assessment and Accreditation of Laboratory 
Animal Care guidance. The UNMC Institutional 
Animal Care and Use Committee approved all 
protocols related to animal experiments and were 
certified to have met the requirements and ethical 
guidelines set forth by the National Institutes of 
Health in handling laboratory animals for research. 
Preparation of rilpivirine (RPV) freebase and 
manufacture of nanoformulated RPV (NRPV)  
RPV freebase was prepared then 
nanoformulated as previously described. [33, 71] 
Nanoformulated RPV (NRPV) was manufactured 
using an Avestin EmulsiFlex-C3 high-pressure 
homogenizer. Briefly, Pluronic 338 (P338) and RPV 
free-base were dispersed in water at concentrations of 
0.5% and 1% (w/v), respectively, and mixed (400-600 
rpm) overnight at room temperature. Presuspensions 
were homogenized at 20,000 psi until homogeneous 
nanocrystals in terms of size (nm) and polydispersity 
(PDI) were produced. NRPV was purified and 
concentrated by centrifugation. Specifically, 
nanoformulations were centrifuged at 5,000 x g for 5 
minutes, at which point supernatants were subject to 
a second spin of 10,000 x g for 5 minutes. Resultant 
pellets were resuspended in endotoxin free water. A 
final centrifugation step of 200 x g for 3 minutes 
removed any aggregated particles. NRPV (size: 341.8 
± 4 nm, PDI: 0.22 ± 0.03, zeta potential: -9.06 ± 0.4 mV) 
was characterized by dynamic light scattering and 
assayed for drug content (56.8 mg/ml) by 
UPLC-UV/Vis using previously described methods. 
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[33, 71] To test drug loading content, NRPV was 
frozen at -80˚C and lyophilized to yield a dry powder. 
Samples were weighed, dissolved in methanol, and 
analyzed by UPLC-UV/Vis. Drug loading was 
calculated by the following equation. Drug loaded (%) 
= (Weight of drug in lyophilized formulation/weight 
of lyophilized formulation) X100. 
Preparation of intrinsically radiolabeled 
177LuBSNR particles 
Intrinsically radiolabeled 177LuBSNRs particles, 
were prepared by a solvothermal technique.[26, 28] A 
typical reaction scheme is available in the 
Supplementary Figure S1 top panel (imaging 
particles). Bismuth neodecanoate (290 mg, ~400 µM) 
and 4 mL of oleic acid (OA) were mixed in a glass vial 
and stirred for 10 min. Subsequently, ~ 1665 MBq (~45 
mCi) of 177LuCl3 and 4 mL ethanol were mixed in a 
separate vial and transferred to the bismuth-oleic acid 
(Bi-OA) mixture. In a 1.5 mL microcentrifuge tube, 
thioacetamide (30 mg, ~ 400 µM) was quickly added 
to 800 µL of oleyl amine (OAm) and the mixture was 
sonicated for 15 minutes to completely dissolve the 
mixtures. After vigorous stirring for 30 minutes, the 
colloidal dark black solution was transferred into a 
250 mL high safety Teflon-lined reactor that was 
placed in a stainless-steel autoclave reactor, sealed 
airtight, and heated at 150°C for 10 hours. The 
systems were then allowed to naturally cool to room 
temperature (around 12 hours). After reaching room 
temperature, the reactor was opened in a controlled, 
radioisotope work station. Fifty milliliters of ethanol 
were added followed by vortexing and sonication. 
The solution was then centrifuged at 976 xg for 30 
minutes at 15°C. 177LuBSNR particles were collected 
and purified by repeating the same ethanol washing 
process three times to remove non-reacted 
components. Radioactivity of 177LuBSNRs was 
measured by gamma counter (CRC®-25R dose 
calibrator, Capintec, Inc, Florham Park, NJ, USA). 
Lipid coated 177LuBSNR particles were prepared by 
the thin-film dispersion technique. First, 100 mg 
L-α-phosphatidylcholine and 50 mg DSPE-PEG2000 
were dissolved in a chloroform/hexane mixture (5:1 
v/v) contained within a round-bottomed flask and 
evaporated to form a thin film using a rotavap 
(Heidolph, Hei-VAP Precision; G3B Vertical, USA). 
The films were dried under vacuum overnight (18 
hours) to ensure the complete removal of organic 
solvents. Second, 177LuBSNRs (50 mg particles; ~ 647.5 
MBq = ~ 17.5 mCi) were dispersed in cyclohexane (2 
mL) followed by bath sonication for 10 minutes to 
achieve a uniform dispersion of the particles in the 
solvent. The 177LuBSNRs-cyclohexane dispersion was 
mixed with 2 mL of 2% (v/v) Tween-80 in a 25 mL 
round-bottom flask and sonicated for 5 minutes to 
form a turbid metalosome emulsion. Third, 
cyclohexane was removed from the 
177LuBSNRs/cyclohexane/Tween-80 emulsion by 
rotavaporation. Lastly, the 177LuBSNRs particle 
solution was transferred to the lipid film coated 
round-bottomed flask and dispersed in the lipid film 
through gentle rotation at 45°C with continuous bath 
sonication. The end product was collected by 
centrifugation at 270 xg for 10 minutes. 177LuBSNRs in 
the supernatant was used for particle size and 
radioactivity analyses. Non-radiolabeled LuBSNRs 
and drug loaded particles were synthesized by the 
same technique except that non-radioactive 175LuCl3 
was used instead of 177LuCl3. BSNRs-RPV particles 
were prepared with 10 mg of RPV drug in the lipid 
film. NRPV suspensions were prepared as described 
previously (supplementary Figure S1 bottom panel 
and SM2).[33] 
Particle characterizations 
The morphology, lattice crystal structure, 
elemental composition, and chemical color mapping 
of the synthesized BSNRs and 177LuBSNRs particles 
were determined by bright field high-resolution 
transmission electron microscopy (HR-TEM), selected 
area electron diffraction (SAED), energy-dispersive 
x-ray spectroscopy (EDX), and scanning transmission 
electron microscopy (STEM) with high-angle annular 
dark-field (HAADF) (FEI Tecnai Osiris S/TEM 
operated at 200 kV). The TEM samples were prepared 
in cyclohexane and dried on a copper grid 
(FCF-400-CU, Electron Microscopy Sciences–EMS, 
Hatfield, PA, USA) at room temperature. Bright field 
images were taken with exposure times of 0.5 s. No 
staining of particles was used, since the heavy metal 
contrast was adequate for imaging. The additional 
gain in speed can also be used to collect EDX 
elemental mappings from a larger field-of-view. The 
lattice fringes of the obtained samples and the 
corresponding SAED patterns were examined using 
HR-TEM at 200 kV. The experimental SAED patterns 
were analyzed using PCED2 software (Landyne 
Software, Lincoln, NE, USA). 
To determine the shape and size of NRPV 
particles, the nanosuspension was vortexed and the 
samples were placed onto a Whatman Nuclepore 
Track-Etch membrane filter, mounted to the 
conductive adhesive tape on the scanning electron 
microscope (SEM) stub, and air-dried overnight. After 
sputter-coating with a thin layer (~5 nm thick) of 
chromium using Denton Desk V sputter, the sample 
was examined with a Hitachi S4700 field-emission 
SEM. For transmission electron microscopy (TEM), 
the NRPV particles suspensions were collected using 
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carbon-formvar coated grids and stained with 1% 
phosphotungstic acid. Samples were examined and 
imaged using a Hitachi H7500 TEM. The particles 
were also characterized by Wavelength Dispersive 
X-ray Fluorescence (WDXRF) analysis using a Rigaku 
WDXRF (Supermini200) spectrometer with high 
resolution and lower detection limits for elemental 
analysis. A 200 W, air cooled, Pd X-ray source was 
operated at 50 kV and 4 mA to produce the excitation 
spectrum with faster elemental detection capability. A 
three-crystal analyzing unit was equipped in the 
system to support the standard LiF (200), PET, and 
RX25 crystals for the detection of the elements 
ranging from ultrafiltration (UF). Particle surface 
chemistry analysis was performed with X-ray 
photoelectron spectroscopy (XPS) and measurements 
were carried out using monochromatic Al Kalpha 
x-ray with an energy of 1486.6 eV by Thermo 
Scientific K-alpha+XPS (Thermo fisher scientific, 
Waltham, MA, USA). Powder X-ray diffraction (XRD) 
analyses of BSNRs, 177LuBSNRs and NRPV were 
performed in the 2θ range of 2–70° using a 
PANalytical Empyrean diffractometer (PANalytical 
Inc.; Westborough, MA, USA) with Cu-Kα radiation 
(1.5418 Å) at 40 kV, 45 mA settings. A mask of 20 mm 
and divergence slit of 1/32° were used on the incident 
beam path. A thin layer of the particle powder sample 
was placed on a zero-background silicon plate and the 
sample holder was continuously spun at the rate of 
22.5 deg/s during all measurements. The PIXcel3D 
detector, equipped with a beam monochromator, 
(PANalytical Inc.; Westborough, MA, USA) was 
scanned at a rate of 0.053 deg/s. Atomic Force 
Microscopy (AFM) images were collected with a 
Nanoscope IV system (Bruker Nano Surfaces, Santa 
Barbara, CA, USA) in Tapping Mode at ambient 
conditions. Silicon probes RTESPA-300 with a 
resonance frequency of ~300 kHz and a spring 
constant of ~40 N/m were used for imaging at a 
scanning rate of 2.0 Hz. Image processing and particle 
size analyses were performed using Femtoscan 
software (Advanced Technologies Center, Moscow, 
Russia). Particle sizes of the BSNRs and NRPV was 
determined by measuring hydrodynamic diameter 
and particle size distribution in water on a Malvern 
Nano-Series Zetasizer system (Malvern Instruments 
Ltd., Malvern, UK). Excitation and emission spectra of 
BSNRs were determined using UV 
spectrophotometry (SpectraMax® M3, Molecular 
Devices, LLC, San Jose, CA, USA). RPV content of 
BSNRs-RPV and NRPV was determined by 
reverse-phase ultra-performance liquid 
chromatography (UPLC) using a Waters Acquity 
UPLC H-Class System with TUV detector and 
Empower 3 software (Waters, Milford, MA, USA) as 
previously described.[33, 71] Bismuth and sulfur 
quantifications were performed by inductively 
coupled plasma mass spectrometry (ICP-MS) at the 
University of Nebraska-Lincoln’s Spectroscopy and 
Biophysics Core Facility, using an Agilent 7500cx 
ICP-MS (Santa Clara, CA, USA) coupled with a 
96-well plate autosampler Model SC/DX4 from 
Elemental Scientific, Inc. (Omaha, NE, USA), 
operating in Mix-Gas collision/reaction mode (3.5 mL 
H2 and 1.5 mL He per minute). Other conditions 
were: plasma power, 1500 W; carrier gas flow, 1 
L/minute; makeup gas flow, 0.15 L/minute; sample 
depth, 8 mm; plasma gas, 15 L/minute. The 
concentrations were calculated against an external 
calibration curve with 50 μg/L of Ga used as internal 
standard (IS) throughout (71Ga isotope). Tissue 
samples were suspended in 4 times the volume of 
metal-grade nitric acid, incubated at room 
temperature for up to 2 hours followed by overnight 
digestion at 65oC. The samples were cooled and 
diluted 20-fold into the autosampler at a final 
concentration of 10 mg/mL.  
Drug loading for BSNRs  
BSNRs-RPV formulations were prepared by 
using a similar technique as for lipid coating of 
177LuBSNRs. First, 10 mg of RPV free base was added 
to a glass vial and completely dissolved in methanol 
with sonication for 10-15 minutes. Second, 100 mg 
L-α-Phosphatidylcholine and 50 mg of DSPE-PEG2000 
were placed in a round bottom flask, chloroform and 
hexane were added along with RPV in same flask. The 
solvent was removed by rotavaporation to create a 
uniform thin lipid film. The film was left to dry in a 
desiccator vacuum overnight to ensure the removal of 
any trace solvent. Third, 100 mg of 177Lu/BSNRs 
particles were dispersed in cyclohexane and sonicated 
for 30 min until completely mixed. Then, 10 mL of 2% 
(v/v) tween 80 was added and the mixture was 
sonicated to form a turbid emulsion. Fourth, 
cyclohexane was removed by rotavaporation and 
afterwards, particles were transferred into the round 
bottom flask with RPV-lipid film for coating process. 
The flask was steadily rotated in warm water with 
gentle sonication to ensured complete dissolution and 
coating of lipid film. The BSNRs-RPV particles were 
purified by centrifugation of the suspension at 270 xg 
(500 rpm) for 10 minutes. Supernatant containing 
particles was used for particle size, drug loading 
quantitation and radioactivity analysis. Metal content 
was analyzed by ICP-MS. For drug quantification 
from nanoparticles, ~50 mg of lyophilized 
nanoparticles was dissolved in 10 mL of DCM: 
methanol (1:1 v/v) mixture. The mixture was then 
bath sonicated for 30 minutes followed by 
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centrifugation at 35,1315× g for 30 minutes. The 
supernatant was collected and DCM was evaporated 
at room temperature. The drug in methanol was 
quantified by UPLC-UV/Vis.[24] 
Radiolabeled particle stability 
The in vitro stability of 177LuBSNRs was 
determined in phosphate-buffered saline (PBS) and 
rat plasma. Briefly, 100 L of 177LuBSNRs (1.85 Mbq = 
~50 Ci) were incubated in 1.5 mL of PBS or rat 
plasma at 4C or 37C for up to 72 hours. After 0, 24, 
48, and 72 hours, the samples were centrifuged at 
2,0817 xg for 30 minutes at 10C (Refrigerated 
Centrifuge 5417R, Eppendorf North America, 
Hauppauge, NY, USA). The supernatant was 
collected into a separate microcentrifuge tube. The 
radioactivity in the pellet and the supernatant were 
measured by gamma counter. To determine percent 
stability the following equation was used; 
Radiolabeling stability (%) = radioactivity in 
pellet/total radioactivity (pellet plus supernatant).[33]  
Macrophage uptake and retention of particles 
The uptake and retention of BSNRs-RPV 
particles were evaluated in human monocyte-derived 
macrophages (MDM) following previously published 
protocols. [24, 33, 35] Briefly, 1.5 x 106 human 
monocytes were seeded into 12-well polystyrene 
tissue culture plates and incubated in Dulbecco’s 
Modified Eagles Medium containing macrophage 
colony stimulating factor for seven days at 37C to 
promote cell differentiation into macrophages 
(MDM).[24, 33, 35] To determine uptake, MDM were 
treated with BSNRs-RPV at a concentration of either 
12.5 g/mL or 25 g/mL (bismuth content) for 2, 4, 6, 
or 8 hours. To determine cell retention, MDM were 
treated with either 12.5 g/mL or 25 g/mL 
BSNRs-RPV for 8 hours. The treatment media was 
removed, cells were washed three times with PBS, 
and treatment-free media was added. Bismuth and 
RPV content in cells were determined at 1, 2, 3, and 5 
days following treatment with half media exchanges 
every other day to maintain cell viability. For both 
uptake and retention, at the specified time points, 
media was removed, cells were washed three times 
with PBS, harvested, and counted, following 
centrifugation at 450 xg for 10 minutes. Cell pellets 
were stored at -20C until analysis. For metal analysis, 
the cell pellet was dissolved in fresh diluted nitric 
acid. Bismuth concentration was determined by 
ICP-MS and reported as µg/106 cells. For RPV 
analysis, 100 L of methanol was added to the cell 
pellet followed by 15 seconds of sonication. The 
mixture was then centrifuged at 450 xg  for 10 minutes 
and the supernatant collected and analyzed by 
UPLC-MS/MS for RPV content.[24, 33, 35] 
Cell changes associated with uptake of BSNRs 
were assessed by TEM, AFM and confocal 
microscopy, taking advantage of BSNRs intrinsic near 
infrared (NIR) fluorescence properties. For confocal 
studies, MDM were cultured on glass coverslips in 12 
well plates at a density of 1.5 x 106 cells/well. MDM 
were then treated with 25 g/mL BSNRs (as bismuth) 
for 8 hours. After particle incubation, treatment media 
was removed and cells were washed three times in 
cold PBS. After washing, the cells were fixed with 
ice-cold 4% paraformaldehyde (PFA) in PBS at room 
temperature for 30 minutes. Glass coverslips with 
fixed cells were then transferred to glass slides. Cell 
nuclei were stained with ProLong Gold AntiFade and 
4’6-diamidino-2-phenylindole (DAPI, Thermo-Fischer 
Scientific, Waltham MA, USA) and images acquired 
using a 63x oil objective on an LSM 710 confocal 
microscope (Carl Zeiss Microimaging, Inc., Dublin, 
CA, USA) interfaced with Image Browser AIM 
software (version 4.2). NIR imaging of particle uptake 
by MDM was performed on an Olympus IX73 
inverted microscope with a xenon excitation source 
and equipped with an Olympus DP80 Digital Camera 
and cellSens Dimension software. Unstained slides 
were imaged for autofluorescence with a FITC filter 
cube, and NIR fluorescence with an ICG filter cube. 
Emission wavelengths were; DAPI: 455 nm; 
TexasRED: 615 nm; ICG: 767 nm. For uptake analysis 
by TEM, cells were scraped, collected from wells, and 
fixed in 0.1 M Sorenson’s phosphate buffer (pH 6.2) 
containing 2% glutaraldehyde and 2% w/v PFA for 24 
hours at 4C. TEM sample preparation, staining, and 
imaging were performed according to previously 
published protocols.[24, 35]  
Visualization of the surface topography of 
BSNR-loaded MDM was evaluated using AFM. 
Coverslips with fixed cells were removed from wells 
and mounted on a slide. Images were acquired in the 
air using an MFP-3DTM system (Asylum Research, 
Santa Barbara, CA, USA) operating in tapping mode. 
AFM probes MSNL-F with a nominal spring constant 
of ∼0.6N/m were used for imaging. Image processing 
was performed using Femtoscan software (Advanced 
Technologies Center, Moscow, Russia).[33] 
Assessment of antiretroviral activities 
Antiretroviral activities of BSNRs-RPV were 
evaluated by measures of HIV reverse transcriptase 
(RT) activity in cell culture medium and HIV-1 p24 
antigen staining of cells and compared to the 
antiretroviral activity of NRPV as previously 
described with the following modifications.[33] First, 
MDM were treated with 12.5 µg/mL or 25 µg/mL 
(bismuth concentration) for 8 hours. Second, cells 
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were challenged with HIV-1ADA at a multiplicity of 
infection (MOI) of 0.1 infectious virions per cell for 16 
hours on day 1, 3, 5, or 8 after treatment removal. 
After an additional 10 days, culture supernatant was 
removed from cells and assessed for progeny virion 
production by RT activity.[33] The cells were fixed 
with 4% PFA for 15 minutes at room temperature and 
then stained with antibodies against HIV-1 p24 as 
previously described.[13, 20, 24, 33] Images were 
analyzed using a Nikon TE300 microscope with a 20 X 
magnification objective. 
Tissue biodistribution of particles 
To determine whether BSNRs could predict ARV 
biodistribution, we designed an in vivo experiment 
comprised of six different treatment groups of 15 
Balb/c mice per group (10 mice for group 5). Each 
group received treatment as a single intravenous 
injection on the first day of the experiment. As shown 
in Table 3 and supplementary Figure S12, the first 
and second groups received NRPV at a dose of 45 
mg/kg (G1) and 5 mg/kg (G2), respectively. Group 3 
received both BSNRs (80 mg/kg, bismuth) and NRPV 
(45 mg/kg) (G3). RPV loaded BSNRs (BSNRs-RPV) 
were administered to the fourth group (G4) at a dose 
of 80 mg/kg bismuth, (~5 mg/kg RPV). Group 5 (G5) 
received 80 mg/kg bismuth as 177LuBSNRs (37 MBq = 
~ 1000 µCi) for SPECT imaging. The sixth group (G6) 
received non-radioactive BSNRs at a dose of 80 
mg/kg bismuth.  
For G1 and G2, which received only NRPV, 
plasma was collected on days 1, 2, 3, 4, 7, 14, 21, and 
28 and analyzed by UPLC-MS/MS for RPV content. 
Out of 15 mice, 5 each were sacrificed and internal 
organs collected on days 2, 5, and 28. These tissues 
were analyzed by UPLC-MS/MS for RPV content. G3 
and G4, which received BSNRs plus NRPV or 
BSNRs-RPV, respectively, underwent similar plasma 
and tissue collection and RPV analysis as G1 and G2, 
however, plasma and tissue were also analyzed by 
ICP-MS for bismuth content. G5 received 177LuBSNRs 
and SPECT imaging was performed on these animals 
at 6, 12, 24, 48, and 120 hours (5 days) post-injection. 
Acquired images were reconstructed to 3D renditions 
and regions of interest (ROIs) were drawn over 
various organs to determine radioactivity 
concentration in counts per minute (CPM)/mm3 
tissue. On days 2 and 5 post-injection, 5 animals were 
sacrificed and liver, spleen, heart, lungs, brain, 
muscle, blood, bone, lymph nodes, stomach, pancreas, 
small intestine, large intestine, bladder, testes, 
kidneys, and tail (injection site) were collected. These 
organs along with the animals’ bedding (excreted 
radioactivity) and carcasses were subjected to gamma 
counting (gamma scintillation spectrometry (Ortec 
NaI(Ti) Scintillation Radiation Detector, Ametek, Oak 
Ridge, TN, USA) and percent injected dose per gram 
of tissue (%ID/g) was determined. G6, which 
received non-radioactive BSNRs, had tissues collected 
on days 2, 5, and 28. Samples were analyzed for 
bismuth content by ICP-MS. 
Various parameters were assessed across groups 
and time to determine the predicative value for 
long-term biodistribution. Pearson’s correlation 
coefficients for two parameter comparisons were 
determined for RPV concentration, bismuth 
concentration, ROIs (SPECT) measurements, as well 
as gamma counter radioactivity measures in liver, 
spleen and lymph nodes. Means of absolute “r” 
values with p ≤ 0.05 were used to create the “multiple 
ribbon bar graph” to summarize the closed correlation 
groups by including time, dose, treatments, and 
measurements of particle components. 
SPECT and gamma scintillation 
determinations biodistribution 
SPECT imaging was performed on G5 mice to 
assess the in vivo biodistribution of 177LuBSNRs. Each 
animal received ~1000 Ci of 177LuBSNRs (~ 80 
mg/kg bismuth). Images were acquired at 6, 12, 24, 
48, and 120 hours post injection using a SPECT/CT 
system (Flex Triumph, TriFoil Imaging, Northridge, 
CA, USA) fitted with a five pinhole (1.0 mm per 
pinhole) collimator. First, CT images were acquired 
using 360 projections over 360° with an X-ray tube 
current of 140 mA and voltage of 75 kilovoltage peak 
(kVp) at a magnification of 2.0 (field of view = 59.2 
mm2). Immediately after, SPECT image acquisition 
was performed with the following parameters; 64 
projections at 15 second per projection over 360° using 
a radius of rotation of 48 mm (field of view = 59 mm2). 
Co-registration of anatomical CT images and 
functional SPECT was performed by 3D visualization 
and analysis software, VivoQuant 3.5 (Invicro Boston, 
MA, USA). ROIs were drawn over various organs and 
radioactivity content and organ volume were 
determined to calculate counts per cubic millimeter 
(mm3). After days 2 and 5 scans, mice were sacrificed 
and various organs including heart, lungs, liver, 
pancreas, stomach, spleen, small intestine, large 
intestine, kidneys, bladder, lymph nodes, muscle, 
bone, brain, testes, injection site (tail), remaining 
carcass and blood were collected, weighed, and 
analyzed ex-vivo for radioactivity using gamma 
counter scintillation spectrometry (ORTEC NaI(Ti) 
Scintillation Radiation Detector, Ametek, Oak Ridge, 
TN, USA). Additionally, animals were individually 
caged so that excreted signal could be measured from 
the bedding. Signal measured was back-calculated to 
the time of injection to account for radioactive decay 
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of 177Lu (t1/2 = 6.64 days).[33] The signal from each 
tissue was normalized to the sum of total counts from 
all sources and then divided by the weight of the 
organ to obtain % ID/g for each tissue. 
Laser ablation inductively coupled plasma 
mass spectrometry (LA-ICP-MS) 
After G3, G4 and G6 animals were sacrificed, 
spleens were collected for LA-ICP-MS analysis. 
Spleen processing and imaging analysis were 
completed as described previously.[38, 107] In brief, 
frozen spleens were sliced to a thickness of 20 μm 
using a LEICA CM1850 cryostat and placed on glass 
slides for either LA-ICP-MS imaging or hematoxylin 
and eosin staining. The staining was performed using 
a rapid Chrome frozen section staining kit (Thermo 
Fisher Scientific, Waltham, MA, USA). For 
LA-ICP-MS, a CETAC LSX-213 G2 laser system and a 
Perkin Elmer Nexion 300X ICP-MS were used. The 
parameters used in the laser ablation system were the 
following: spot size = 50 μm, scan rate of 15 μm/s, 10 
Hz laser frequency, 10 s of shutter delay, and a carrier 
He gas flow of 0.6 L/minute. The ICP-MS parameters 
were the following: nebulizer argon flow rate = 0.7 
L/minute, plasma argon flow rate = 16.5 L/minute, 
auxiliary argon flow rate = 1.4 L/minute, analog stage 
voltage = -1650 V, and pulse stage voltage = 1000 V. 
Three elements were detected, including bismuth, 
iron, and zinc. Images were reconstructed and 
analyzed in a custom script written in Python that 
uses multiple metals to identify sub-organ regions of 
interest. In short, the script uses statistical k-mean 
clustering to distinguish the red pulp, white pulp, and 
marginal zones in the spleen, enabling a relative 
measure of bismuth in each sub-organ region. 
Autoradiography 
Livers and spleens were excised at 2 and 5 days 
post-injection from mice treated with 177LuBSNRs 
(G5). Collected tissues were washed with deionized 
water and immediately embedded into optimal 
cutting temperature (O.C.T) compound (Fisher 
HealthCare, Waltham, MA, USA). Cryostat sections 
(10 μm) of tissue samples were prepared and exposed 
to a phosphor screen overnight in the dark (Leica 
CM1850, Leica Biosystems Inc, Buffalo Grove, IL, 
USA). The phosphor screen was subsequently imaged 
by a Typhoon FLA 9500 variable mode imager (GE 
Lifesciences, Pittsburg, PA, USA) at 25 μm resolution. 
UPLC-MS/MS analysis of drug in plasma and 
tissues  
Plasma samples were prepared for 
UPLC-MS/MS analysis for RPV content according to 
our previously published work. [33, 71] In brief, 10 µL 
of internal standard (IS) solution (250 ng/mL 
indinavir and 500 ng/ml lopinavir; final 
concentration 25 ng/ml indinavir, 50 ng/ml 
lopinavir) was added to 25 µl of plasma along with 1 
mL of ice-cold MS -grade acetonitrile. After vortexing 
and centrifugation, supernatants were evaporated 
and then reconstituted in 100 µL 50% (v/v) methanol 
in water. For tissue analyses, 100 mg of tissue was 
homogenized in 4 volumes of 90% (v/v) methanol in 
water. Standard curves were prepared in blank mouse 
plasma or tissue in the range of 0.2–2000 ng/mL RPV 
with 10 µL of IS added. An ACQUITY UPLC-BEH 
Shield RP18 column (1.7 µm, 2.1 mm x 100 mm) was 
used for chromatographic separation of 10 µL of 
plasma or tissue samples using a 7-minute gradient of 
mobile phase A (7.5 mM ammonium bicarbonate in 
Optima-grade water adjusted to pH 7 using acetic 
acid) and mobile phase B (100% Optima-grade 
methanol) at a flow rate of 0.25 mL/minute. For more 
exact details please see our previously published 
work. [33, 71] 
Bismuth quantitation 
Bismuth concentrations in plasma and tissues 
were determined in mouse plasma and tissues by 
ICP-MS metal at the University of Nebraska-Lincoln's 
Spectroscopy and Biophysics core facility.[33] 
Tissue localization and toxicity 
Particle distribution within the spleen and liver 
from mice treated with BSNRs (G6) was evaluated via 
TEM. For TEM examination, tissue samples were 
fixed in TEM buffer at room temperature. Tissue 
processing and sectioning were performed as 
previously described.[24] In vivo toxicity of 
BSNRs-RPV was determined by histological 
examination. Here, 5 m sections of 
paraffin-embedded tissues were fixed on glass slides 
and stained with H&E. Images were captured using a 
Nuance EX multispectral imaging system affixed to a 
Nikon Eclipse E800 microscope (Nikon Instruments, 
Melville, NY, USA) fitted with a 20X objective. 
Histopathological assessment was conducted in 
accordance with the guidelines of the Society of 
Toxicologic Pathology. Serum chemistry was assessed 
using a VetScan comprehensive diagnostic profile 
disc and a VetScan VS-2 instrument (Abaxis 
Veterinary Diagnostics, Union City, CA, USA).[24, 33, 
35] 
Statistical analyses 
For all studies, data were analyzed using 
GraphPad Prism 8.2 software (GraphPad, La Jolla, 
CA, USA) and are presented as the mean ± standard 
error of the mean (SEM). Experiments with multiple 
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time points were analyzed using two-way factorial 
ANOVA and Bonferroni's post hoc tests for multiple 
comparisons. Pearson’s correlation analyses were 
performed for multiple tissues, doses, and data 
acquisition times from SPECT, ICP-MS and 
UPLC-MS/MS. Two-parameter comparisons yielding 
a Pearson coefficient greater than 0.5 (r > 0.5) were 
considered of predictive value. 
Abbreviation 
177Lu: 177Lutetium 
177LuBSNRs: 177Lutetium-bismuth sulfide nanorods 
AFM: atomic force microscopy 
ART: antiretroviral therapy 
ARV: antiretroviral drugs 
Bq: becquerel 
BSA: bovine serum albumin 
BSNRs: bismuth sulfide nanorods 
BSNRs-RPV: bismuth sulfide nanorods rilpivirine 
Ci: curie 
DAPI: 4’6-diamidino-2-phenylindole 
DCM: dichloromethane 
DMSO: dimethyl sulfoxide 
DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[amino(polyethylene 
glycol)-2000] 
EC50: 50% maximal effective concentration 
GALT: gut-associated lymphoid tissue 
HIV-1: human immunodeficiency virus type 1 
HR-TEM: high-resolution transmission electron 
microscopy 
IV: intravenous 
IM: intramuscular 
kVp: kilovoltage peak 
LA ARV: long acting antiretroviral drugs 
LA-ICP-MS: laser ablation inductively coupled 
plasma mass spectrometry 
LA NRPV: long acting nanoformulated rilpivirine 
LASER ART: long acting slow effective release 
antiretroviral therapy 
MBq: mega becquerel 
MDM: human monocyte-derived macrophage 
MOI: multiplicity of infection 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide 
NanoART: nanoformulated antiretroviral therapy 
NIR: near Infrared 
NRPV: nanoformulated rilpivirine 
OA: oleic acid  
OAm: oleyl amine  
PBS: phosphate-buffered saline 
PC: phosphatidylcholine 
PD: pharmacodynamics 
PDI: polydispersity index 
PFA: paraformaldehyde 
PK: pharmacokinetic 
RB: round-bottom flask 
ROI: region of interest 
RPV: rilpivirine 
RT: reverse transcriptase 
SAED: selected area diffraction 
SEM: scanning electron microscope 
SPECT: single photon emission computed 
tomography  
STEM: Scanning transmission electron microscopy 
TEM: transmission electron microscopy 
μCi: microcurie 
UPLC-MS/MS: ultra-performance liquid chromate-
graphy tandem mass spectrometry 
UPLC: liquid chromatography 
XRD: x-ray diffraction 
XRF: x-ray fluorescence 
XPS: x-ray photoelectron spectroscopy 
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